Skip to main content
Top
Published in:

Open Access 27-03-2025 | Vasculitis | Case Report

A case of digital vasculitis in anti-synthetase syndrome (Anti-OJ subtype)

Authors: Deniz AK, Richard J. Stratton

Published in: BMC Rheumatology | Issue 1/2025

Login to get access

Abstract

Anti-synthetase syndrome is a rare autoimmune disorder characterised by the presence of autoantibodies against aminoacyl transfer RNA synthetases. We report a unique case of a 54-year-old woman with anti-OJ anti-synthetase syndrome, characterised by the atypical occurrence of digital vasculitis in conjunction with the classic manifestations of anti-synthetase syndrome. Our patient presented with digital vasculitis affecting the right third and fourth fingers, rapidly evolving interstitial lung disease of the organising pneumonia subtype, sub-clinical myositis, arthritis and mechanic’s hands. Notably, she had no prior history of Raynaud’s phenomenon. Serological tests revealed positive anti-OJ antibodies and weakly positive anti-MI2 antibodies. Our patient’s condition was managed with intravenous methylprednisolone then after stepped down to prednisolone and mycophenolate mofetil with successful therapeutic response.
Current literature primarily highlights Raynaud’s phenomenon and vasculopathy-related ischemia, whether occlusive or non-occlusive in anti-synthetase syndrome. This case study identifies digital vasculitis as a distinctive complication of anti-synthetase syndrome, anti-OJ subtype. It emphasises the importance of recognising vascular complications, including vasculitis, even when classic signs like Raynaud’s phenomenon are absent. Further research is crucial to fully understand the range of vascular manifestations associated with anti-synthetase syndrome.
Literature
2.
go back to reference Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464–74.PubMed Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464–74.PubMed
4.
7.
go back to reference Disdier P, Bolla G, Harle JR, Pache X, Weiller-Merli C, Marco MS, Figarella-Branger D, Weiller PJ. Nécroses digitales révélatrices D’un syndrome des antisynthétases [Digital necrosis disclosing antisynthetase syndrome]. Ann Dermatol Venereol. 1994;121(6–7):493–5. French. PMID: 7702284.PubMed Disdier P, Bolla G, Harle JR, Pache X, Weiller-Merli C, Marco MS, Figarella-Branger D, Weiller PJ. Nécroses digitales révélatrices D’un syndrome des antisynthétases [Digital necrosis disclosing antisynthetase syndrome]. Ann Dermatol Venereol. 1994;121(6–7):493–5. French. PMID: 7702284.PubMed
Metadata
Title
A case of digital vasculitis in anti-synthetase syndrome (Anti-OJ subtype)
Authors
Deniz AK
Richard J. Stratton
Publication date
27-03-2025
Publisher
BioMed Central
Published in
BMC Rheumatology / Issue 1/2025
Electronic ISSN: 2520-1026
DOI
https://doi.org/10.1186/s41927-025-00484-0

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more